Differential Toxicity Profile: Tarlatamab vs Traditional Cytotoxic Therapies

Summary for Physicians:

Differential Toxicity Profile: Tarlatamab vs Traditional Cytotoxic Therapies

• Tarlatamab (immunotherapy):
• Immune-related toxicities: Includes cytokine release syndrome, immune effector cell–associated neurotoxicity syndrome, and immune-related adverse events (eg, rash, colitis)

• Less myelosuppression compared with traditional chemotherapy

• Onset of adverse effects is typically within 24 to 48 hours post infusion
• Traditional cytotoxic therapies:
• Common toxicities: Myelosuppression, nausea/vomiting, alopecia, fatigue, and mucositis

• Delayed onset of adverse effects (often seen after several cycles)

• Dose-limiting toxicities often related to bone marrow suppression

Key Differences:

• Tarlatamab may cause acute immune reactions but spares long-term organ damage compared with cytotoxic therapies.

Traditional chemotherapies are associated with cumulative toxicities over time, particularly myelosuppression, which is less of a concern with tarlatamab.